A Spanish pharmaceutical company reported increased annual profits Wednesday, boosted by strong performance of its mental health medication and blood-thinning products despite facing challenges in other business areas.
Laboratorios Farmaceuticos Rovi announced its annual net profit climbed 3% to reach 140.4 million euros in 2025, even as the company’s total operating revenue dropped 3% to 743.5 million euros.
The profit increase was primarily driven by robust sales growth in the company’s specialty pharmaceutical division, which saw revenue jump 11% to 473.9 million euros. This growth was powered by a dramatic 97% surge in sales of Okedi, the company’s schizophrenia treatment, along with a 7% increase in sales of heparin products, which include various blood-thinning medications.
However, Rovi faced significant headwinds in its contract manufacturing operations, where revenue plummeted 20% to 269.5 million euros. This decline was attributed to minimal revenue from Moderna-related contracts and reduced production volumes for the vaccine manufacturer.
The company’s gross profit managed to grow 3% to 494.7 million euros, supported by 36.3 million euros in research and development assistance and lower costs for raw materials used in blood-thinning medications.
Looking ahead, Rovi plans to reward shareholders with a proposed dividend of 0.96 euros per share, representing approximately 35% of profits. Company executives project that operating revenue will expand by a high single-digit to low double-digit percentage in 2026.
